CLINICAL STUDY
Are we making progress with percutaneous saphenous vein graft treatment?
A comparison of 1990 to 1994 and 1995 to 1998 results
Mun K. Hong, MD, FACC*,
Roxana Mehran, MD, FACC ,
George Dangas, MD, PhD, FACC,
Gary S. Mintz, MD, FACC,
Alexandra Lansky, MD, FACC,
Kenneth M. Kent, MD, PhD, FACC ,
Augusto D. Pichard, MD, FACC,
Lowell F. Satler, MD, FACC,
Gregg W. Stone, MD, FACC and
Martin B. Leon, MD, FACC
* Department of Internal Medicine, Division of Cardiology, Cornell University-New York Presbyterian Hospital, New York, New York, USA
Cardiovascular Research Foundation, New York, New York, USA
Washington Hospital Center, Washington, DC, USA
Manuscript received December 12, 2000;
revised manuscript received March 19, 2001,
accepted March 29, 2001.
Reprint requests and correspondence: Dr. Mun K. Hong, Director, Cardiovascular Intervention and Research, Cornell University-New York Presbyterian Hospital, Starr Pavilion 4, 520 East 70th Street, New York, New York 10021
mkh2003{at}med.cornell.edu
OBJECTIVES
We sought to determine whether strategies to reduce procedural distal embolization and late repeat revascularization have resulted in more favorable outcomes after saphenous vein graft (SVG) angioplasty.
BACKGROUND
Angioplasty of SVG lesions has been associated with frequent procedural and late cardiac events. Therefore, evolving strategies have been attempted to improve outcomes after SVG angioplasty.
METHODS
We compared our earlier experience (1990 to 1994) of 1,055 patients with 1,412 SVG lesions with a recent group (1995 to 1998) of 964 patients with 1,315 lesions.
RESULTS
Baseline characteristics were similar between the groups. However, there were significantly more unfavorable lesion characteristics (older, longer and significantly more degenerated SVGs) in the recent series. Between the two periods, there was decreased use of atheroablative devices, whereas stent use increased. The procedural success rates (96.6% vs. 96.1%) were similar. However, one-year outcome (event-free survival) was significantly improved in the more recent experience (70.7% vs. 59.1%, p < 0.0001), especially late mortality (6.1% vs. 11.3%, p < 0.0001). Multivariate analysis showed stent use to be the only protective variable for both periods.
CONCLUSIONS
This study shows that despite higher risk lesions, strategies to reduce distal embolization have maintained high procedural success. Late cardiac events, including mortality, have also been substantially reduced.
|
Abbreviations and Acronyms
| | CK-MB | = creatine kinase-MB isoenzyme | | MI | = myocardial infarction | | SVG | = saphenous vein graft | | TLR | = target lesion revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
D. J. Kereiakes, M. A. Turco, J. Breall, N. Z. Farhat, R. L. Feldman, B. McLaurin, J. J. Popma, L. Mauri, P. Zimetbaum, J. Massaro, et al.
A Novel Filter-Based Distal Embolic Protection Device for Percutaneous Intervention of Saphenous Vein Graft Lesions: Results of the AMEthyst Randomized Controlled Trial
J. Am. Coll. Cardiol. Intv.,
June 1, 2008;
1(3):
248 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Coolong, D. S. Baim, R. E. Kuntz, A. J. O'Malley, S. Marulkar, D. E. Cutlip, J. J. Popma, and L. Mauri
Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients
Circulation,
February 12, 2008;
117(6):
790 - 797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Berry, J.-C. Tardif, and M. G. Bourassa
Coronary Heart Disease in Patients With Diabetes: Part II: Recent Advances in Coronary Revascularization
J. Am. Coll. Cardiol.,
February 13, 2007;
49(6):
643 - 656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jonas, G. W. Stone, R. Mehran, J. Hermiller, R. Feldman, H. C. Herrmann, D. A. Cox, R. E. Kuntz, J. J. Popma, C. Rogers, et al.
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection
Eur. Heart J.,
April 2, 2006;
27(8):
920 - 928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Schachinger, C. W. Hamm, T. Munzel, M. Haude, S. Baldus, E. Grube, T. Bonzel, T. Konorza, R. Koster, R. Arnold, et al.
A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts
J. Am. Coll. Cardiol.,
October 15, 2003;
42(8):
1360 - 1369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Baim
Percutaneous treatment of saphenous vein graft disease: The ongoing challenge
J. Am. Coll. Cardiol.,
October 15, 2003;
42(8):
1370 - 1372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, C. Rogers, J. Hermiller, R. Feldman, P. Hall, R. Haber, A. Masud, P. Cambier, R. P. Caputo, M. Turco, et al.
Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts
Circulation,
August 5, 2003;
108(5):
548 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Traverse, M. R. Mooney, W. R. Pedersen, J. D. Madison, T. F. Flavin, V. R. Kshettry, T. D. Henry, F. Eales, L. D. Joyce, and R. W. Emery
Clinical, Angiographic, and Interventional Follow-Up of Patients With Aortic-Saphenous Vein Graft Connectors
Circulation,
July 29, 2003;
108(4):
452 - 456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Stankovic, A. Colombo, P. Presbitero, F. van den Branden, L. Inglese, C. Cernigliaro, L. Niccoli, A. L. Bartorelli, P. Rubartelli, N. Reifart, et al.
Randomized Evaluation of Polytetrafluoroethylene-Covered Stent in Saphenous Vein Grafts: The Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial
Circulation,
July 8, 2003;
108(1):
37 - 42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.J. de Feyter
Percutaneous Treatment of Saphenous Vein Bypass Graft Obstructions: A Continuing Obstinate Problem
Circulation,
May 13, 2003;
107(18):
2284 - 2286.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Singh, U. Rosenschein, K. K.L. Ho, P. B. Berger, R. Kuntz, and D. R. Holmes, Jr
Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis: A Randomized Study (ATLAS)
Circulation,
May 13, 2003;
107(18):
2331 - 2336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes
Platelet Glycoprotein IIb/IIIa Inhibition and Atheroembolism During Bypass Graft Angioplasty: A Cup Half Full
Circulation,
December 10, 2002;
106(24):
2994 - 2996.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Roffi, D. Mukherjee, D. P. Chew, D. L. Bhatt, L. Cho, M. A. Robbins, K. M. Ziada, D. M. Brennan, S. G. Ellis, and E. J. Topol
Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts: A Pooled Analysis of Five Randomized Clinical Trials
Circulation,
December 10, 2002;
106(24):
3063 - 3067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, C. Rogers, S. Ramee, C. White, R. E. Kuntz, J. J. Popma, J. George, S. Almany, and S. Bailey
Distal filter protection during saphenous vein graft stenting: Technical and clinical correlates of efficacy
J. Am. Coll. Cardiol.,
November 20, 2002;
40(10):
1882 - 1888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
